Stifel analyst Derek Archila initiated Pacira (PCRX) with a Sell rating and a price target of $41, saying the stock price is not "particularly cheap" following the rally driven by an upward revision to Exparel sales guidance during its Q2 earnings call. The analyst adds that the approval of Heron's (HRTX) HTX-011 also creates a "medium- to long-term headwind" for Pacira.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Heron Therapeutics (HRTX),... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here